The correlation between systolic blood pressure and angiotensinogen levels in hypertensive patients with g-6a agt treated with angiotensin ii receptor blocker: A preliminary study

The existence of genetic variant-6 abnormal glucose tolerance (AGT) is thought to be a functional area that affects the basal transcriptional activity resulted in increased angiotensinogen levels. Single nucleotide polymorphisms (SNP) of G-6A was genotyped by using polymerase chain reaction (PCR) followed by sequencing. Serum angiotensinogen levels were measured using ELISA. In the present study, there was no statistical difference of baseline angiotensinogen levels found among genotypes. Also, there were no significant differences found in angiotensinogen levels as well as in the changes of angiotensinogen levels after a 5-month treatment of angiotensin II receptor blocker (ARB). There was also no statistically significant correlation between blood pressure and angiotensinogen levels at baseline among genotypes. However, mean SBP after 5 months of ARB treatment was found to significantly correlate with serum angiotensinogen levels in patients with AA genotype (p = 0.05; r =-0.28) but not with other genotype. However, this preliminary study should be followed by increasing the sample size to confirm the result.